Compare
Enliven Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc. vs Ardelyx, Inc. vs Biohaven Ltd.
| Latest fiscal year | Enliven Therapeutics, Inc. ELVN | Rhythm Pharmaceuticals, Inc. RYTM | Ardelyx, Inc. ARDX | Biohaven Ltd. BHVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $189.76M | $407.32M | n/a |
| Revenue growth (YoY) | n/a | +45.8% | +22.1% | n/a |
| Gross margin | n/a | 89.7% (computed) | 90.3% (computed) | n/a |
| Operating margin | n/a | -101.2% | -10.1% | n/a |
| Net margin | n/a | -103.6% | -15.1% | n/a |
| Net income | -$103.69M | -$196.54M | -$61.60M | -$738.82M |
| EPS (Diluted) | -$1.83 | -$3.11 | -$0.26 | -$6.86 |
| Operating cash flow | -$70.30M | -$115.67M | -$42.48M | -$609.44M |
| Free cash flow | -$70.46M | -$116.63M | -$43.98M | -$610.15M |
| Cash & equivalents | $98.90M | $54.30M | $68.00M | $229.96M |
| Total assets | $476.17M | $480.20M | $501.60M | $451.45M |
| Total liabilities | $16.57M | $210.17M | $334.65M | $399.38M |
| Shareholders' equity | $459.60M | $139.07M | $166.95M | $52.07M |
| Return on year-end equity | -22.6% | -141.3% | -36.9% | n/m |
| Shares outstanding | 59.44M | 67.21M | 244.35M | 132.78M |
Revenue, most recent five fiscal years
| Fiscal year | Enliven Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. | Ardelyx, Inc. | Biohaven Ltd. |
|---|---|---|---|---|
| Latest | n/a | $189.76M Ended 2025-12-31 | $407.32M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $130.13M Ended 2024-12-31 | $333.62M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $77.43M Ended 2023-12-31 | $124.46M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $23.64M Ended 2022-12-31 | $52.16M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $3.15M Ended 2021-12-31 | $10.10M Ended 2021-12-31 | n/a |